CCTG Tumour Tissue Data Repository, Canada

Certification Status: Approved

Registration Status: Completed

Objective: The CCTG TTDR contains unique disease specific collections which are linked to an associated clinical dataset. This represents a "real" tumour bank in that tissue is collected from institutions across Canada and the world, cataloged and housed centrally in the Department of Pathology and Molecular Medicine at Queen's University Our mission is to establish a collection of specimens stored in house and linked with clinical trials dataset. Access to the specimens permits the assessment of prognostic factors in determining the outcome of disease, the assessment of predictive factors to various chemotherapeutic agents and treatment regimens, and to facilitate the understanding of the basic biological and genetic mechanisms of cancer.

Registered Biobank Name	CCTG Tumour Tissue Data Repository (TTDR)
Biobank Leader	Shakeel Virk
Country	Canada
Email for biobank inquiries	virks@queensu.ca
Principal Investigator	Dr. Lois Shepherd; Dr. Janet Dancey
Website	https://www.ctg.queensu.ca/public/cctg-tissue-bank-correlative-science/
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).